What is claimed is:

1. A compound that is seladelpar or a salt thereof for use in treating an intrahepatic cholestatic disease, where the daily dose of the compound is 5-50 mg when the dose is calculated as seladelpar.

2. The compound for use according to claim 1 where the compound is seladelpar L-lysine dihydrate salt.

3. The compound for use according to claim 1 or 2 where the compound is administered orally.

4. The compound for use according to any one of claims 1 to 3 where the daily dose of seladelpar or a salt thereof is 10-35 mg, when the dose is calculated as seladelpar.

5. The compound for use according to any one of claims 1 to 4 where the seladelpar or a salt thereof is administered once/day.

6. The compound for use according to any one of claims 1 to 5 where the intrahepatic cholestatic disease is primary biliary cholangitis, primary sclerosing cholangitis, progressive familial intrahepatic cholestasis, or Alagille syndrome.

7. The compound for use according to claim 6 where the intrahepatic cholestatic disease is primary biliary cholangitis.

8. The compound for use according to claim 6 where the intrahepatic cholestatic disease is primary sclerosing cholangitis.

9. The compound for use according to claim 6 where the intrahepatic cholestatic disease is progressive familial intrahepatic cholestasis.

10. The compound for use according to claim 6 where the intrahepatic cholestatic disease is Alagille syndrome.